Literature DB >> 26584601

Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis.

Ekaterina Safroneeva1, Alex Straumann2, Michael Coslovsky1, Marcel Zwahlen1, Claudia E Kuehni1, Radoslaw Panczak1, Nadine A Haas1, Jeffrey A Alexander3, Evan S Dellon4, Nirmala Gonsalves5, Ikuo Hirano5, John Leung6, Christian Bussmann7, Margaret H Collins8, Robert O Newbury9, Giovanni De Petris10, Thomas C Smyrk11, John T Woosley12, Pu Yan13, Guang-Yu Yang14, Yvonne Romero15, David A Katzka3, Glenn T Furuta16, Sandeep K Gupta17, Seema S Aceves18, Mirna Chehade19, Jonathan M Spergel20, Alain M Schoepfer21.   

Abstract

BACKGROUND & AIMS: It is not clear whether symptoms alone can be used to estimate the biologic activity of eosinophilic esophagitis (EoE). We aimed to evaluate whether symptoms can be used to identify patients with endoscopic and histologic features of remission.
METHODS: Between April 2011 and June 2014, we performed a prospective, observational study and recruited 269 consecutive adults with EoE (67% male; median age, 39 years old) in Switzerland and the United States. Patients first completed the validated symptom-based EoE activity index patient-reported outcome instrument and then underwent esophagogastroduodenoscopy with esophageal biopsy collection. Endoscopic and histologic findings were evaluated with a validated grading system and standardized instrument, respectively. Clinical remission was defined as symptom score <20 (range, 0-100); histologic remission was defined as a peak count of <20 eosinophils/mm(2) in a high-power field (corresponds to approximately <5 eosinophils/median high-power field); and endoscopic remission as absence of white exudates, moderate or severe rings, strictures, or combination of furrows and edema. We used receiver operating characteristic analysis to determine the best symptom score cutoff values for detection of remission.
RESULTS: Of the study subjects, 111 were in clinical remission (41.3%), 79 were in endoscopic remission (29.7%), and 75 were in histologic remission (27.9%). When the symptom score was used as a continuous variable, patients in endoscopic, histologic, and combined (endoscopic and histologic remission) remission were detected with area under the curve values of 0.67, 0.60, and 0.67, respectively. A symptom score of 20 identified patients in endoscopic remission with 65.1% accuracy and histologic remission with 62.1% accuracy; a symptom score of 15 identified patients with both types of remission with 67.7% accuracy.
CONCLUSIONS: In patients with EoE, endoscopic or histologic remission can be identified with only modest accuracy based on symptoms alone. At any given time, physicians cannot rely on lack of symptoms to make assumptions about lack of biologic disease activity in adults with EoE. ClinicalTrials.gov, Number: NCT00939263.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disease Monitoring; EEsAI; Endoscopic Grading; Remission

Mesh:

Year:  2015        PMID: 26584601      PMCID: PMC6011000          DOI: 10.1053/j.gastro.2015.11.004

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  35 in total

1.  Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.

Authors:  Ranjan Dohil; Robert Newbury; Lyman Fox; John Bastian; Seema Aceves
Journal:  Gastroenterology       Date:  2010-05-07       Impact factor: 22.682

2.  Manometric features of eosinophilic esophagitis in esophageal pressure topography.

Authors:  S Roman; I Hirano; M A Kwiatek; N Gonsalves; J Chen; P J Kahrilas; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2010-11-23       Impact factor: 3.598

3.  The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life.

Authors:  T H Taft; E Kern; M A Kwiatek; I Hirano; N Gonsalves; L Keefer
Journal:  Aliment Pharmacol Ther       Date:  2011-08-02       Impact factor: 8.171

4.  Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis.

Authors:  Marc E Rothenberg; Seema Aceves; Peter A Bonis; Margaret H Collins; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; Chris A Liacouras; Phil E Putnam; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Glenn T Furuta
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

Review 5.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

6.  Dissociation between symptoms and histological severity in pediatric eosinophilic esophagitis.

Authors:  Scott Pentiuk; Phillip E Putnam; Margaret H Collins; Marc E Rothenberg
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-02       Impact factor: 2.839

Review 7.  Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment.

Authors:  Glenn T Furuta; Chris A Liacouras; Margaret H Collins; Sandeep K Gupta; Chris Justinich; Phil E Putnam; Peter Bonis; Eric Hassall; Alex Straumann; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2007-08-08       Impact factor: 22.682

8.  Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis.

Authors:  Alain M Schoepfer; Alex Straumann; Radoslaw Panczak; Michael Coslovsky; Claudia E Kuehni; Elisabeth Maurer; Nadine A Haas; Yvonne Romero; Ikuo Hirano; Jeffrey A Alexander; Nirmala Gonsalves; Glenn T Furuta; Evan S Dellon; John Leung; Margaret H Collins; Christian Bussmann; Peter Netzer; Sandeep K Gupta; Seema S Aceves; Mirna Chehade; Fouad J Moawad; Felicity T Enders; Kathleen J Yost; Tiffany H Taft; Emily Kern; Marcel Zwahlen; Ekaterina Safroneeva
Journal:  Gastroenterology       Date:  2014-08-23       Impact factor: 22.682

Review 9.  Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review.

Authors:  Evan S Dellon; Ademola Aderoju; John T Woosley; Robert S Sandler; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2007-07-07       Impact factor: 10.864

10.  Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases.

Authors:  Robert Fiorentino; Gumei Liu; Anne R Pariser; Andrew E Mulberg
Journal:  J Allergy Clin Immunol       Date:  2012-07-31       Impact factor: 10.793

View more
  79 in total

Review 1.  Application of the Functional Lumen Imaging Probe to Esophageal Disorders.

Authors:  Dustin A Carlson; Ikuo Hirano
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

Review 2.  Biological therapies for eosinophilic gastrointestinal diseases.

Authors:  Joshua B Wechsler; Ikuo Hirano
Journal:  J Allergy Clin Immunol       Date:  2018-05-31       Impact factor: 10.793

Review 3.  A Conceptual Approach to Understanding Treatment Response in Eosinophilic Esophagitis.

Authors:  Evan S Dellon; Sandeep K Gupta
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-30       Impact factor: 11.382

Review 4.  Eosinophilic esophagitis phenotypes: Ready for prime time?

Authors:  Dan Atkins; Glenn T Furuta; Chris A Liacouras; Jonathan M Spergel
Journal:  Pediatr Allergy Immunol       Date:  2017-05-04       Impact factor: 6.377

Review 5.  White Paper AGA: Drug Development for Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Stuart Spechler; Glenn Furuta; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-22       Impact factor: 11.382

6.  Unsedated In-office Transgastrostomy Esophagoscopy to Monitor Therapy in Pediatric Esophageal Disease.

Authors:  Caroline H T Hall; Nathalie Nguyen; Glenn T Furuta; Jeremy Prager; Emily Deboer; Robin Deterding; Calies Menard-Katcher; Kelley E Capocelli; Robert E Kramer; Joel A Friedlander
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-01       Impact factor: 2.839

7.  No Maintenance, No Gain in Long-term Treatment of Eosinophilic Esophagitis.

Authors:  Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2019-02       Impact factor: 11.382

Review 8.  Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach.

Authors:  Mery Munoz-Persy; Alfredo J Lucendo
Journal:  Eur J Pediatr       Date:  2018-03-17       Impact factor: 3.183

9.  Prospective assessment of serum periostin as a biomarker for diagnosis and monitoring of eosinophilic oesophagitis.

Authors:  E S Dellon; L L Higgins; R Beitia; S Rusin; J T Woosley; R Veerappan; S R Selitsky; J S Parker; R M Genta; R H Lash; R Aranda; R J Peach; M Grimm
Journal:  Aliment Pharmacol Ther       Date:  2016-05-18       Impact factor: 8.171

10.  Cost Utility Analysis of Topical Steroids Compared With Dietary Elimination for Treatment of Eosinophilic Esophagitis.

Authors:  Cary C Cotton; Daniel Erim; Swathi Eluri; Sarah H Palmer; Daniel J Green; W Asher Wolf; Thomas M Runge; Stephanie Wheeler; Nicholas J Shaheen; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.